DOI: 10.1007/s12012-007-0023-3. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

10.1007/s12012-007-0023-3

Crossref journal-article

Springer Science and Business Media LLC

Cardiovascular Toxicology (297)

Bibliography

Hasinoff, B. B., & Herman, E. H. (2007). Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovascular Toxicology, 7(2), 140â144.

Authors 2

Brian B. Hasinoff (first)
Eugene H. Herman (additional)

References 23 Referenced 104

Swain, S. M., & Vici, P. (2004). The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. Journal of Cancer Research and Clinical Oncology, 130, 1–7. (10.1007/s00432-003-0498-7) / Journal of Cancer Research and Clinical Oncology by S. M. Swain (2004)
Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004). Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone-dependent and independent mechanisms. Methods in Enzymology, 378, 340–361. (10.1016/S0076-6879(04)78025-8) / Methods in Enzymology by G. Minotti (2004)
Herman, E. H., & Ferrans, V. J. (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treatment Reviews, 17, 155–160. (10.1016/0305-7372(90)90040-M) / Cancer Treatment Reviews by E. H. Herman (1990)
Hasinoff, B. B., Hellmann, K., Herman, E. H., & Ferrans, V. J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1–28. (10.2174/0929867305666220314194045) / Current Medicinal Chemistry by B. B. Hasinoff (1998)
Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., & Marusak, R. A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. Journal of Inorganic Biochemistry, 78, 209–216. (10.1016/S0162-0134(00)00013-1) / Journal of Inorganic Biochemistry by N. K. Diop (2000)
Hasinoff, B. B., Schroeder, P. E., & Patel, D. (2003). The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Molecular Pharmacology, 64, 670–678. (10.1124/mol.64.3.670) / Molecular Pharmacology by B. B. Hasinoff (2003)
Hasinoff, B. B. (2002). Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovascular Toxiciology, 2, 111–118. (10.1385/CT:2:2:111) / Cardiovascular Toxiciology by B. B. Hasinoff (2002)
Fortune, J. M., & Osheroff, N. (2000). Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Progress in Nucleic Acid Research Molecular Biology, 64, 221–253. (10.1016/S0079-6603(00)64006-0) / Progress in Nucleic Acid Research Molecular Biology by J. M. Fortune (2000)
Swift, L. M., & Sarvazyan, N. (2000). Localization of dichlorofluorescin in cardiac myocytes: Implications for assessment of oxidative stress. American Journal of Physiology and Heart and Circulatory Physiology, 278, H982–H990. (10.1152/ajpheart.2000.278.3.H982) / American Journal of Physiology and Heart and Circulatory Physiology by L. M. Swift (2000)
Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003). Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovascular Toxiciology, 3, 89–99. (10.1385/CT:3:2:89) / Cardiovascular Toxiciology by B. B. Hasinoff (2003)
Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. American Journal of Physiology, 271, H2079–H2085. / American Journal of Physiology by N. Sarvazyan (1996)
Malisza, K. L., & Hasinoff, B. B. (1996). Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane). Redox Report, 2, 69–73. (10.1080/13510002.1996.11747029) / Redox Report by K. L. Malisza (1996)
Schroeder, P. E., Jensen, P. B., Sehested, M., Hofland, K. F., Langer, S. W., & Hasinoff, B. B. (2003). Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemotherapy and Pharmacology, 52, 167–174. (10.1007/s00280-003-0619-7) / Cancer Chemotherapy and Pharmacology by P. E. Schroeder (2003)
Schroeder, P. E., & Hasinoff, B. B. (2005). Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal chelating form in the rat. Drug Metabolism and Disposition, 33, 1367–1372. (10.1124/dmd.105.005546) / Drug Metabolism and Disposition by P. E. Schroeder (2005)
Hasinoff, B. B., Kuschak, T. I., Yalowich, J. C., & Creighton, A. M. (1995). A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochemical Pharmacology, 50, 953–958. (10.1016/0006-2952(95)00218-O) / Biochemical Pharmacology by B. B. Hasinoff (1995)
Classen, S., Olland, S., & Berger, J. M. (2003). Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proceedings of the National Academy Sciences of the United States of America, 100, 14510. (10.1073/pnas.2436153100) / Proeedings of the National Academy Sciences of the United States of America by S. Classen (2003)
Hasinoff, B. B., Abram, M. E., Chee, G.-L., Huebner, E., Byard, E. H., Barnabé, N., Ferrans, V. J., Yu, Z.-X., & Yalowich, J. C. (2000). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. The Journal of Pharmacology and Experimental Therapeutics, 295, 474–483. / The Journal of Pharmacology and Experimental Therapeutics by B. B. Hasinoff (2000)
Hasinoff, B. B., Abram, M. E., Barnabé, N., Khelifa, T., Allan, W. P., & Yalowich, J. C. (2001). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Molecular Pharmacology, 59, 453–461. (10.1124/mol.59.3.453) / Molecular Pharmacology by B. B. Hasinoff (2001)
Hasinoff, B. B., Yalowich, J. C., Ling, Y., & Buss, J. L. (1996). The effect of dexrazoxane (ICRF-87) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs, 7, 558–567. (10.1097/00001813-199607000-00011) / Anticancer Drugs by B. B. Hasinoff (1996)
Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Demant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389–393. (10.1016/0006-2952(93)90514-W) / Biochemical Pharmacology by M. Sehested (1993)
Hasinoff, B. B., Kuschak, T. I., Creighton, A. M., Fattman, C. L., Allan, W. P., Thampatty, P., & Yalowich, J. C. (1997). Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochemical Pharmacology, 53, 1843–1853. (10.1016/S0006-2952(97)00013-0) / Biochemical Pharmacology by B. B. Hasinoff (1997)
Pouillart, P. (2004). Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treatment Reviews, 30, 643–650. (10.1016/j.ctrv.2004.06.002) / Cancer Treatment Reviews by P. Pouillart (2004)
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Velez-Garcia, E., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology, 15, 1318–1332. (10.1200/JCO.1997.15.4.1318) / Journal of Clinical Oncology by S. M. Swain (1997)

Dates

Type	When
Created	18 years, 3 months ago (May 14, 2007, 8:52 a.m.)
Deposited	3 years, 3 months ago (May 18, 2022, 4:05 p.m.)
Indexed	1 month, 1 week ago (July 22, 2025, 6:44 a.m.)
Issued	18 years, 4 months ago (April 25, 2007)
Published	18 years, 4 months ago (April 25, 2007)
Published Online	18 years, 4 months ago (April 25, 2007)
Published Print	18 years, 2 months ago (June 1, 2007)

Funders 0

None

BibTeX

@article{Hasinoff_2007, title={Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?}, volume={7}, ISSN={1559-0259}, url={http://dx.doi.org/10.1007/s12012-007-0023-3}, DOI={10.1007/s12012-007-0023-3}, number={2}, journal={Cardiovascular Toxicology}, publisher={Springer Science and Business Media LLC}, author={Hasinoff, Brian B. and Herman, Eugene H.}, year={2007}, month=apr, pages={140–144} }

JSON

{
  "indexed": {
    "date-parts": [
      [
        2025,
        7,
        22
      ]
    ],
    "date-time": "2025-07-22T10:44:48Z",
    "timestamp": 1753181088611
  },
  "reference-count": 23,
  "publisher": "Springer Science and Business Media LLC",
  "issue": "2",
  "license": [
    {
      "start": {
        "date-parts": [
          [
            2007,
            4,
            25
          ]
        ],
        "date-time": "2007-04-25T00:00:00Z",
        "timestamp": 1177459200000
      },
      "content-version": "tdm",
      "delay-in-days": 0,
      "URL": "https://www.springer.com/tdm"
    },
    {
      "start": {
        "date-parts": [
          [
            2007,
            4,
            25
          ]
        ],
        "date-time": "2007-04-25T00:00:00Z",
        "timestamp": 1177459200000
      },
      "content-version": "vor",
      "delay-in-days": 0,
      "URL": "https://www.springer.com/tdm"
    }
  ],
  "content-domain": {
    "domain": [
      "link.springer.com"
    ],
    "crossmark-restriction": false
  },
  "published-print": {
    "date-parts": [
      [
        2007,
        6
      ]
    ]
  },
  "DOI": "10.1007/s12012-007-0023-3",
  "type": "journal-article",
  "created": {
    "date-parts": [
      [
        2007,
        5,
        14
      ]
    ],
    "date-time": "2007-05-14T12:52:14Z",
    "timestamp": 1179147134000
  },
  "page": "140-144",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "source": "Crossref",
  "is-referenced-by-count": 104,
  "title": "Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?",
  "prefix": "10.1007",
  "volume": "7",
  "author": [
    {
      "given": "Brian B.",
      "family": "Hasinoff",
      "sequence": "first",
      "affiliation": []
    },
    {
      "given": "Eugene H.",
      "family": "Herman",
      "sequence": "additional",
      "affiliation": []
    }
  ],
  "member": "297",
  "published-online": {
    "date-parts": [
      [
        2007,
        4,
        25
      ]
    ]
  },
  "reference": [
    {
      "key": "23_CR1",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "DOI": "10.1007/s00432-003-0498-7",
      "volume": "130",
      "author": "S. M. Swain",
      "year": "2004",
      "unstructured": "Swain, S. M., & Vici, P. (2004). The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. Journal of Cancer Research and Clinical Oncology, 130, 1\u20137.",
      "journal-title": "Journal of Cancer Research and Clinical Oncology"
    },
    {
      "key": "23_CR2",
      "doi-asserted-by": "crossref",
      "first-page": "340",
      "DOI": "10.1016/S0076-6879(04)78025-8",
      "volume": "378",
      "author": "G. Minotti",
      "year": "2004",
      "unstructured": "Minotti, G., Recalcati, S., Menna, P., Salvatorelli, E., Corna, G., & Cairo, G. (2004). Doxorubicin cardiotoxicity and the control of iron metabolism: Quinone-dependent and independent mechanisms. Methods in Enzymology, 378, 340\u2013361.",
      "journal-title": "Methods in Enzymology"
    },
    {
      "key": "23_CR3",
      "doi-asserted-by": "publisher",
      "first-page": "155",
      "DOI": "10.1016/0305-7372(90)90040-M",
      "volume": "17",
      "author": "E. H. Herman",
      "year": "1990",
      "unstructured": "Herman, E. H., & Ferrans, V. J. (1990). Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treatment Reviews, 17, 155\u2013160.",
      "journal-title": "Cancer Treatment Reviews"
    },
    {
      "key": "23_CR4",
      "doi-asserted-by": "crossref",
      "first-page": "1",
      "DOI": "10.2174/0929867305666220314194045",
      "volume": "5",
      "author": "B. B. Hasinoff",
      "year": "1998",
      "unstructured": "Hasinoff, B. B., Hellmann, K., Herman, E. H., & Ferrans, V. J. (1998). Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Current Medicinal Chemistry, 5, 1\u201328.",
      "journal-title": "Current Medicinal Chemistry"
    },
    {
      "key": "23_CR5",
      "doi-asserted-by": "publisher",
      "first-page": "209",
      "DOI": "10.1016/S0162-0134(00)00013-1",
      "volume": "78",
      "author": "N. K. Diop",
      "year": "2000",
      "unstructured": "Diop, N. K., Vitellaro, L. K., Arnold, P., Shang, M., & Marusak, R. A. (2000). Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: Solid state structure, solution thermodynamics, and DNA cleavage activity. Journal of Inorganic Biochemistry, 78, 209\u2013216.",
      "journal-title": "Journal of Inorganic Biochemistry"
    },
    {
      "key": "23_CR6",
      "doi-asserted-by": "publisher",
      "first-page": "670",
      "DOI": "10.1124/mol.64.3.670",
      "volume": "64",
      "author": "B. B. Hasinoff",
      "year": "2003",
      "unstructured": "Hasinoff, B. B., Schroeder, P. E., & Patel, D. (2003). The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Molecular Pharmacology, 64, 670\u2013678.",
      "journal-title": "Molecular Pharmacology"
    },
    {
      "key": "23_CR7",
      "doi-asserted-by": "publisher",
      "first-page": "111",
      "DOI": "10.1385/CT:2:2:111",
      "volume": "2",
      "author": "B. B. Hasinoff",
      "year": "2002",
      "unstructured": "Hasinoff, B. B. (2002). Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage. Cardiovascular Toxiciology, 2, 111\u2013118.",
      "journal-title": "Cardiovascular Toxiciology"
    },
    {
      "key": "23_CR8",
      "doi-asserted-by": "publisher",
      "first-page": "221",
      "DOI": "10.1016/S0079-6603(00)64006-0",
      "volume": "64",
      "author": "J. M. Fortune",
      "year": "2000",
      "unstructured": "Fortune, J. M., & Osheroff, N. (2000). Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Progress in Nucleic Acid Research Molecular Biology, 64, 221\u2013253.",
      "journal-title": "Progress in Nucleic Acid Research Molecular Biology"
    },
    {
      "key": "23_CR9",
      "doi-asserted-by": "crossref",
      "first-page": "H982",
      "DOI": "10.1152/ajpheart.2000.278.3.H982",
      "volume": "278",
      "author": "L. M. Swift",
      "year": "2000",
      "unstructured": "Swift, L. M., & Sarvazyan, N. (2000). Localization of dichlorofluorescin in cardiac myocytes: Implications for assessment of oxidative stress. American Journal of Physiology and Heart and Circulatory Physiology, 278, H982\u2013H990.",
      "journal-title": "American Journal of Physiology and Heart and Circulatory Physiology"
    },
    {
      "key": "23_CR10",
      "doi-asserted-by": "publisher",
      "first-page": "89",
      "DOI": "10.1385/CT:3:2:89",
      "volume": "3",
      "author": "B. B. Hasinoff",
      "year": "2003",
      "unstructured": "Hasinoff, B. B., Schnabl, K. L., Marusak, R. A., Patel, D., & Huebner, E. (2003). Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovascular Toxiciology, 3, 89\u201399.",
      "journal-title": "Cardiovascular Toxiciology"
    },
    {
      "key": "23_CR11",
      "first-page": "H2079",
      "volume": "271",
      "author": "N. Sarvazyan",
      "year": "1996",
      "unstructured": "Sarvazyan, N. (1996). Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. American Journal of Physiology, 271, H2079\u2013H2085.",
      "journal-title": "American Journal of Physiology"
    },
    {
      "key": "23_CR12",
      "doi-asserted-by": "crossref",
      "first-page": "69",
      "DOI": "10.1080/13510002.1996.11747029",
      "volume": "2",
      "author": "K. L. Malisza",
      "year": "1996",
      "unstructured": "Malisza, K. L., & Hasinoff, B. B. (1996). Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane). Redox Report, 2, 69\u201373.",
      "journal-title": "Redox Report"
    },
    {
      "key": "23_CR13",
      "doi-asserted-by": "publisher",
      "first-page": "167",
      "DOI": "10.1007/s00280-003-0619-7",
      "volume": "52",
      "author": "P. E. Schroeder",
      "year": "2003",
      "unstructured": "Schroeder, P. E., Jensen, P. B., Sehested, M., Hofland, K. F., Langer, S. W., & Hasinoff, B. B. (2003). Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemotherapy and Pharmacology, 52, 167\u2013174.",
      "journal-title": "Cancer Chemotherapy and Pharmacology"
    },
    {
      "key": "23_CR14",
      "doi-asserted-by": "publisher",
      "first-page": "1367",
      "DOI": "10.1124/dmd.105.005546",
      "volume": "33",
      "author": "P. E. Schroeder",
      "year": "2005",
      "unstructured": "Schroeder, P. E., & Hasinoff, B. B. (2005). Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal chelating form in the rat. Drug Metabolism and Disposition, 33, 1367\u20131372.",
      "journal-title": "Drug Metabolism and Disposition"
    },
    {
      "key": "23_CR15",
      "doi-asserted-by": "publisher",
      "first-page": "953",
      "DOI": "10.1016/0006-2952(95)00218-O",
      "volume": "50",
      "author": "B. B. Hasinoff",
      "year": "1995",
      "unstructured": "Hasinoff, B. B., Kuschak, T. I., Yalowich, J. C., & Creighton, A. M. (1995). A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochemical Pharmacology, 50, 953\u2013958.",
      "journal-title": "Biochemical Pharmacology"
    },
    {
      "key": "23_CR16",
      "doi-asserted-by": "publisher",
      "first-page": "14510",
      "DOI": "10.1073/pnas.2436153100",
      "volume": "100",
      "author": "S. Classen",
      "year": "2003",
      "unstructured": "Classen, S., Olland, S., & Berger, J. M. (2003). Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proceedings of the National Academy Sciences of the United States of America, 100, 14510.",
      "journal-title": "Proeedings of the National Academy Sciences of the United States of America"
    },
    {
      "key": "23_CR17",
      "first-page": "474",
      "volume": "295",
      "author": "B. B. Hasinoff",
      "year": "2000",
      "unstructured": "Hasinoff, B. B., Abram, M. E., Chee, G.-L., Huebner, E., Byard, E. H., Barnab\u00e9, N., Ferrans, V. J., Yu, Z.-X., & Yalowich, J. C. (2000). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells. The Journal of Pharmacology and Experimental Therapeutics, 295, 474\u2013483.",
      "journal-title": "The Journal of Pharmacology and Experimental Therapeutics"
    },
    {
      "key": "23_CR18",
      "doi-asserted-by": "crossref",
      "first-page": "453",
      "DOI": "10.1124/mol.59.3.453",
      "volume": "59",
      "author": "B. B. Hasinoff",
      "year": "2001",
      "unstructured": "Hasinoff, B. B., Abram, M. E., Barnab\u00e9, N., Khelifa, T., Allan, W. P., & Yalowich, J. C. (2001). The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Molecular Pharmacology, 59, 453\u2013461.",
      "journal-title": "Molecular Pharmacology"
    },
    {
      "key": "23_CR19",
      "doi-asserted-by": "publisher",
      "first-page": "558",
      "DOI": "10.1097/00001813-199607000-00011",
      "volume": "7",
      "author": "B. B. Hasinoff",
      "year": "1996",
      "unstructured": "Hasinoff, B. B., Yalowich, J. C., Ling, Y., & Buss, J. L. (1996). The effect of dexrazoxane (ICRF-87) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs, 7, 558\u2013567.",
      "journal-title": "Anticancer Drugs"
    },
    {
      "key": "23_CR20",
      "doi-asserted-by": "publisher",
      "first-page": "389",
      "DOI": "10.1016/0006-2952(93)90514-W",
      "volume": "46",
      "author": "M. Sehested",
      "year": "1993",
      "unstructured": "Sehested, M., Jensen, P. B., Sorensen, B. S., Holm, B., Friche, E., & Demant, E. J. F. (1993). Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology, 46, 389\u2013393.",
      "journal-title": "Biochemical Pharmacology"
    },
    {
      "key": "23_CR21",
      "doi-asserted-by": "publisher",
      "first-page": "1843",
      "DOI": "10.1016/S0006-2952(97)00013-0",
      "volume": "53",
      "author": "B. B. Hasinoff",
      "year": "1997",
      "unstructured": "Hasinoff, B. B., Kuschak, T. I., Creighton, A. M., Fattman, C. L., Allan, W. P., Thampatty, P., & Yalowich, J. C. (1997). Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochemical Pharmacology, 53, 1843\u20131853.",
      "journal-title": "Biochemical Pharmacology"
    },
    {
      "key": "23_CR22",
      "doi-asserted-by": "publisher",
      "first-page": "643",
      "DOI": "10.1016/j.ctrv.2004.06.002",
      "volume": "30",
      "author": "P. Pouillart",
      "year": "2004",
      "unstructured": "Pouillart, P. (2004). Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. Cancer Treatment Reviews, 30, 643\u2013650.",
      "journal-title": "Cancer Treatment Reviews"
    },
    {
      "key": "23_CR23",
      "doi-asserted-by": "crossref",
      "first-page": "1318",
      "DOI": "10.1200/JCO.1997.15.4.1318",
      "volume": "15",
      "author": "S. M. Swain",
      "year": "1997",
      "unstructured": "Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., Speyer, J., Mittelman, A., Reddy, S., Pendergrass, K., Velez-Garcia, E., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997). Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology, 15, 1318\u20131332.",
      "journal-title": "Journal of Clinical Oncology"
    }
  ],
  "container-title": "Cardiovascular Toxicology",
  "original-title": [],
  "language": "en",
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s12012-007-0023-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s12012-007-0023-3/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s12012-007-0023-3",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s12012-007-0023-3.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "deposited": {
    "date-parts": [
      [
        2022,
        5,
        18
      ]
    ],
    "date-time": "2022-05-18T20:05:50Z",
    "timestamp": 1652904350000
  },
  "score": 1,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s12012-007-0023-3"
    }
  },
  "subtitle": [],
  "short-title": [],
  "issued": {
    "date-parts": [
      [
        2007,
        4,
        25
      ]
    ]
  },
  "references-count": 23,
  "journal-issue": {
    "issue": "2",
    "published-print": {
      "date-parts": [
        [
          2007,
          6
        ]
      ]
    }
  },
  "alternative-id": [
    "23"
  ],
  "URL": "http://dx.doi.org/10.1007/s12012-007-0023-3",
  "relation": {},
  "ISSN": [
    "1530-7905",
    "1559-0259"
  ],
  "subject": [],
  "container-title-short": "Cardiovasc Toxicol",
  "published": {
    "date-parts": [
      [
        2007,
        4,
        25
      ]
    ]
  },
  "assertion": [
    {
      "value": "25 April 2007",
      "order": 1,
      "name": "first_online",
      "label": "First Online",
      "group": {
        "name": "ArticleHistory",
        "label": "Article History"
      }
    }
  ]
}